NO20053246L - Kondensert 1,3-dihydroimidazol-ringforbindelse. - Google Patents
Kondensert 1,3-dihydroimidazol-ringforbindelse.Info
- Publication number
- NO20053246L NO20053246L NO20053246A NO20053246A NO20053246L NO 20053246 L NO20053246 L NO 20053246L NO 20053246 A NO20053246 A NO 20053246A NO 20053246 A NO20053246 A NO 20053246A NO 20053246 L NO20053246 L NO 20053246L
- Authority
- NO
- Norway
- Prior art keywords
- condensed
- ring compound
- optionally substituted
- dihydroimidazole ring
- nitrogen
- Prior art date
Links
- -1 1,3-dihydroimidazole ring compound Chemical class 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 abstract 1
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- AIDS & HIV (AREA)
- Cardiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002352186 | 2002-12-04 | ||
| PCT/JP2003/015402 WO2004050656A1 (ja) | 2002-12-04 | 2003-12-02 | １，３−ジヒドロ−イミダゾール縮合環化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20053246D0 NO20053246D0 (no) | 2005-07-01 |
| NO20053246L true NO20053246L (no) | 2005-08-30 |
Family
ID=32463216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20053246A NO20053246L (no) | 2002-12-04 | 2005-07-01 | Kondensert 1,3-dihydroimidazol-ringforbindelse. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7524847B2 (pl) |
| EP (1) | EP1568699A4 (pl) |
| JP (1) | JP4279784B2 (pl) |
| KR (1) | KR100867484B1 (pl) |
| CN (1) | CN100376573C (pl) |
| AU (1) | AU2003302657B8 (pl) |
| BR (1) | BR0316991A (pl) |
| CA (1) | CA2507763A1 (pl) |
| IL (1) | IL168784A (pl) |
| MX (1) | MXPA05005983A (pl) |
| NO (1) | NO20053246L (pl) |
| NZ (1) | NZ540495A (pl) |
| PL (1) | PL377187A1 (pl) |
| RU (1) | RU2328498C9 (pl) |
| WO (1) | WO2004050656A1 (pl) |
| ZA (1) | ZA200504973B (pl) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1338595B1 (en) | 2002-02-25 | 2006-05-03 | Eisai Co., Ltd. | Xanthine derivatives as DPP-IV inhibitors |
| US20060100199A1 (en) | 2002-06-06 | 2006-05-11 | Seiji Yoshikawa | Novel condensed imidazole derivatives |
| CA2518465A1 (en) | 2003-03-25 | 2004-10-14 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| US7638638B2 (en) | 2003-05-14 | 2009-12-29 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| KR20060041309A (ko) | 2003-08-13 | 2006-05-11 | 다케다 야쿠힌 고교 가부시키가이샤 | ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도 |
| JP2008501714A (ja) * | 2004-06-04 | 2008-01-24 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼインヒビター |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| AU2006290205B2 (en) | 2005-09-14 | 2012-12-13 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors for treating diabetes |
| CA2622642C (en) | 2005-09-16 | 2013-12-31 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| JP5606734B2 (ja) | 2006-04-25 | 2014-10-15 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| US20090124610A1 (en) * | 2006-04-25 | 2009-05-14 | Gordon Saxty | Pharmaceutical compounds |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| BRPI0818533B8 (pt) | 2007-10-11 | 2021-05-25 | Astrazeneca Ab | composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto |
| NZ590688A (en) * | 2008-08-05 | 2012-09-28 | Daiichi Sankyo Co Ltd | imidazo[4,5-b]pyridin-2-one derivatives |
| ES2665277T3 (es) * | 2009-03-13 | 2018-04-25 | Katholieke Universiteit Leuven K.U. Leuven R&D | Análogos de purina y su uso como agentes inmunosupresores |
| CN102127070A (zh) * | 2010-01-15 | 2011-07-20 | 山东轩竹医药科技有限公司 | 吡啶并环衍生物 |
| CN102153538B (zh) * | 2010-02-11 | 2013-12-11 | 山东轩竹医药科技有限公司 | 苯并环衍生物 |
| CN102276627B (zh) * | 2010-04-29 | 2013-07-31 | 山东轩竹医药科技有限公司 | 吡啶并杂环衍生物 |
| CN102234281B (zh) * | 2010-04-29 | 2013-03-27 | 山东轩竹医药科技有限公司 | 嘧啶并环衍生物 |
| WO2012131399A1 (en) | 2011-04-01 | 2012-10-04 | Astrazeneca Ab | Therapeutic treatment |
| EP2730575B1 (en) * | 2011-07-09 | 2015-09-16 | Xuanzhu Pharma Co., Ltd. | Crystal form i of salt of dipeptidyl peptidase-iv inhibitor and preparation method and use thereof |
| PT2785349T (pt) | 2011-11-30 | 2019-12-11 | Astrazeneca Ab | Tratamento combinado de cancro |
| US8501724B1 (en) * | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
| AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
| WO2015078799A1 (en) * | 2013-11-27 | 2015-06-04 | Bayer Pharma Aktiengesellschaft | Glucose transport inhibitors |
| WO2020048347A1 (zh) * | 2018-09-04 | 2020-03-12 | 上海再极医药科技有限公司 | 氨基嘧啶并五元杂环化合物、其中间体、制备方法、药物组合物及应用 |
| EP3876939A4 (en) | 2018-11-07 | 2022-08-10 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| EP3876930A4 (en) | 2018-11-07 | 2022-07-20 | Dana-Farber Cancer Institute, Inc. | BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF |
| WO2020097400A1 (en) | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof |
| CN109608462B (zh) * | 2018-12-15 | 2021-11-23 | 华南理工大学 | 一种7-烃基-9-烷氧/硫基嘌呤-8-酮类化合物及其合成方法与在药物中的应用 |
| BR112022022409A2 (pt) | 2020-05-06 | 2023-02-07 | Ajax Therapeutics Inc | 6-heteroarilóxi benzimidazóis e azabenzimidazóis como inibidores de jak2 |
| WO2022140527A1 (en) | 2020-12-23 | 2022-06-30 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| WO2023086320A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of jak2 |
| CA3234638A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8515934D0 (en) * | 1985-06-24 | 1985-07-24 | Janssen Pharmaceutica Nv | (4-piperidinomethyl and-hetero)purines |
| US5057517A (en) * | 1987-07-20 | 1991-10-15 | Merck & Co., Inc. | Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents |
| NZ225447A (en) | 1987-07-20 | 1991-12-23 | Merck & Co Inc | Piperazinyl derivatives of purine and purine isosteres and pharmaceutical compositions |
| JP2000086663A (ja) * | 1998-09-09 | 2000-03-28 | Taisho Pharmaceut Co Ltd | アリールテトラヒドロピリジン誘導体 |
| AU756702B2 (en) | 1999-03-11 | 2003-01-23 | Taisho Pharmaceutical Co., Ltd. | Carbamoyl tetrahydropyridine derivatives |
| JP2001151777A (ja) * | 1999-03-11 | 2001-06-05 | Taisho Pharmaceut Co Ltd | カルバモイルテトラヒドロピリジン誘導体 |
| EP1338595B1 (en) | 2002-02-25 | 2006-05-03 | Eisai Co., Ltd. | Xanthine derivatives as DPP-IV inhibitors |
| US20060100199A1 (en) * | 2002-06-06 | 2006-05-11 | Seiji Yoshikawa | Novel condensed imidazole derivatives |
| EP1557165A4 (en) | 2002-09-26 | 2008-12-03 | Eisai R&D Man Co Ltd | COMBINED MEDICINE |
| CA2502356A1 (en) * | 2002-10-15 | 2004-04-29 | Synta Pharmaceuticals Corp. | Aromatic bicyclic heterocyles to modulate 1l - 12 production |
| CA2543707A1 (en) | 2003-10-31 | 2005-05-19 | Takeda Pharmaceutical Company Limited | Nitrogen-containing fused heterocyclic compounds |
| KR101099206B1 (ko) * | 2004-02-05 | 2011-12-27 | 프로비오드룩 아게 | 신규한 글루타미닐 시클라제 저해제 |
-
2003
- 2003-12-02 MX MXPA05005983A patent/MXPA05005983A/es unknown
- 2003-12-02 JP JP2004556886A patent/JP4279784B2/ja not_active Expired - Fee Related
- 2003-12-02 WO PCT/JP2003/015402 patent/WO2004050656A1/ja not_active Ceased
- 2003-12-02 RU RU2005120780/04A patent/RU2328498C9/ru not_active IP Right Cessation
- 2003-12-02 KR KR1020057010179A patent/KR100867484B1/ko not_active Expired - Fee Related
- 2003-12-02 PL PL377187A patent/PL377187A1/pl not_active Application Discontinuation
- 2003-12-02 BR BR0316991-0A patent/BR0316991A/pt not_active IP Right Cessation
- 2003-12-02 EP EP03812368A patent/EP1568699A4/en not_active Withdrawn
- 2003-12-02 CA CA002507763A patent/CA2507763A1/en not_active Abandoned
- 2003-12-02 AU AU2003302657A patent/AU2003302657B8/en not_active Ceased
- 2003-12-02 NZ NZ540495A patent/NZ540495A/en not_active IP Right Cessation
- 2003-12-02 CN CNB2003801095193A patent/CN100376573C/zh not_active Expired - Fee Related
- 2003-12-02 US US10/537,227 patent/US7524847B2/en not_active Expired - Fee Related
-
2005
- 2005-05-25 IL IL168784A patent/IL168784A/en not_active IP Right Cessation
- 2005-06-20 ZA ZA200504973A patent/ZA200504973B/en unknown
- 2005-07-01 NO NO20053246A patent/NO20053246L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20050087825A (ko) | 2005-08-31 |
| JP4279784B2 (ja) | 2009-06-17 |
| RU2328498C2 (ru) | 2008-07-10 |
| AU2003302657B2 (en) | 2009-09-24 |
| AU2003302657A1 (en) | 2004-06-23 |
| NO20053246D0 (no) | 2005-07-01 |
| BR0316991A (pt) | 2005-10-25 |
| IL168784A (en) | 2010-12-30 |
| CN100376573C (zh) | 2008-03-26 |
| EP1568699A1 (en) | 2005-08-31 |
| ZA200504973B (en) | 2006-04-26 |
| US20060111362A1 (en) | 2006-05-25 |
| RU2005120780A (ru) | 2006-01-20 |
| PL377187A1 (pl) | 2006-01-23 |
| US7524847B2 (en) | 2009-04-28 |
| NZ540495A (en) | 2007-09-28 |
| CA2507763A1 (en) | 2004-06-17 |
| MXPA05005983A (es) | 2005-08-18 |
| AU2003302657B8 (en) | 2009-12-03 |
| WO2004050656A1 (ja) | 2004-06-17 |
| AU2003302657A2 (en) | 2004-06-23 |
| CN1745080A (zh) | 2006-03-08 |
| KR100867484B1 (ko) | 2008-11-06 |
| JPWO2004050656A1 (ja) | 2006-03-30 |
| EP1568699A4 (en) | 2007-08-15 |
| RU2328498C9 (ru) | 2008-12-10 |
| HK1086556A1 (zh) | 2006-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1568699A4 (en) | 1,3-DIHYDROIMIDAZOLE CONNECTION WITH CONDENSED RING | |
| NL300927I1 (nl) | tivozanib of een zout of hydraat ervan, in het bijzonder het hydrochloride-monohydraat | |
| ATE401311T1 (de) | Kondensierte heterozyklische verbindungen als petidase inhibitoren | |
| AP1902A (en) | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials | |
| NO20033848D0 (no) | Nitrogenholdige heteroarylforbindelser med en HIV integrase inhiberende aktivitet | |
| BRPI0211844B8 (pt) | composto de ácido fenóxi-acético ou um de seus sais farmaceuticamente aceitáveis, e, composição farmacêutica | |
| DE60212867D1 (de) | Thiazolylsubstituierte aminopyrimidine als pflanzenschutzmittel | |
| CY1113782T1 (el) | Παραγωγα 11-υδροξυ-5η-πυρρολο[2,1-c][1,4]βενζοδιαζεπιν-5-ονης ως ενδιαμεσα κλειδια για την παρασκευη c2 υποκατεστημενων πυρρολοβενζοδιαζεπινων | |
| DK0634408T3 (da) | Depsipeptidderivater, fremstilling og anvendelse deraf | |
| EP1724258A4 (en) | HETEROARYLPHENYLHARNSTOFFDERIVAT | |
| ATE338461T1 (de) | Pyrazolpyrimidinfungizide | |
| TW200602322A (en) | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs | |
| ATE553758T1 (de) | Hemmer für die produktion und freisetzung entzündlicher zytokine | |
| AU7517400A (en) | N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent | |
| ID25649A (id) | Turunan-turunan sikloalkena, produksi serta penggunaannya | |
| WO2004031145A3 (en) | Lactam-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor xa inhibitors | |
| ATE305777T1 (de) | Mittel zur verhinderung der chronischen abstossreaktion infolge einer organtransplantation | |
| DE60239170D1 (de) | Bicyclische Verbindungen | |
| ID24846A (id) | Turunan-turunan bifenilamidina | |
| MY140749A (en) | Novel piperidine compound | |
| DE60002558D1 (de) | Derivate der Phosphonsäure zur Inhibierung von Carboxypeptidase B | |
| DK1554285T3 (da) | Kemisk mellemprodukt | |
| DE60225019D1 (de) | Nicht-nucleosidische inhibitoren der reverse transkriptase | |
| ATE420068T1 (de) | Reverse hydroxamsäurederivate | |
| BR0307424A (pt) | Compostos heterocìclicos com atividade inibidora de elastase e seus intermediários |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |